A Study of RBT-9 in Healthy Volunteers and Volunteers With Stage 3/4 Chronic Kidney Disease

Exclusion Criteria

• •1. History of malignancy, except carcinoma in situ in the cervix, early stage prostate cancer or non-melanoma skin cancers. Cancer free for less than 5 years.
• •2. Use of investigational drugs or participation in another clinical trial within 30 days or 5 half-lives prior to Screening, whichever was longer.
• •3. Serum ferritin \>500 ng/mL or received IV iron within 28 days of Screening.
• •4. Women who are pregnant, breastfeeding, or planning to become pregnant while participating in the study.
• •5. Any significant acute or chronic diseases, excluding CKD (≥ 15 ml/min); if CKD is present, those not at their baseline of renal function.
• •6. Abnormal Baseline liver tests or hepatitis serologies that suggest active infection.
• •7. Regular use of drugs of abuse and/or positive findings on urinary drug screening.
• •8. Current tobacco use and/or positive findings on urinary cotinine screening.
• •9. Severely physically or mentally incapacitated and who, in the opinion of Investigator, are unable to perform the subjects' tasks associated with the protocol.
• •10. Presence of any condition which, in the opinion of the Investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated.
• •11. History of photosensitivity or active skin disease which, in the opinion of the Investigator, could increase the risk of photosensitivity.
• •12. Known hypersensitivity or previous anaphylaxis to RBT-9 or tin-based product.